FREM1 mRNA levels were associated with tumor infiltrating lymphocytes. (A) The average expression of the LYM metagene signature [PTPRC (CD45), CD53, LCP2 (SLP-76), LAPTM5, DOCK2, IL10RA, CYBB and CD48, ITGB2 (LFA-1) and EVI2B] in breast cancers from the TCGA database relative to the FREM1 mRNA level. (B–D) Tumor purity, immune score and stromal score were analyzed using the ESTIMATE algorithm from GEO (N = 237) and TCGA (N = 1097) database. (E) GSEA analysis was used to demonstrate the correlation between FREM1 expression and the KEGG enriched pathway. (F) Immune and inflammation response genes, the JAK-STAT signaling pathway and interferon-stimulated genes were analyzed by RNA-seq in BT474 cancer cells. (G) CXCL8, CXCL10, CXCL11 and the interferon stimulation genes, ISG15 and MX1, were analyzed by Q-PCR in BT474 cancer cells.